ArticleFrontiers in cardiovascular medicine2026
Nonlinear HbA1c thresholds reveal accelerated atherogenic remodeling and improved risk reclassification in type 2 diabetes.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between HbA1c and red cell distribution width-standard deviation in newly diagnosed, treatment-naïve type 2 diabetes mellitus: a retrospective cross-sectional study.BMC endocrine disorders · 2026Article
- Central adiposity and sex influence lipid and glucose indices in Mexican adults: implications for metabolic risk assessment.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysglycemia, lipid metabolism, and cardiovascular disease (CVD) progression in type 2 diabetes (T2D) are closely interconnected, yet the non-linear lipid remodeling processes underlying atherogenic dyslipidemia remain insufficiently defined. This study aimed to identify HbA1c thresholds associated with accelerated lipid-driven atherogenesis, quantify the mediating role of the triglyceride-to-HDL cholesterol ratio (TG/HDL-C)-a surrogate of insulin-resistance-related lipid metabolism-and assess the incremental predictive value of the Atherogenic Index of Plasma (AIP) within the clinically ambiguous "glycemic gray zone." A total of 271 adults with T2D not receiving lipid-lowering therapy were retrospectively grouped by HbA1c: good (<7.0%), moderate (7.0%-8.49%), and poor (≥8.5%) control. Atherogenic lipid burden was evaluated using AIP, Castelli indices, TG/HDL-C, non-HDL cholesterol, and remnant cholesterol. Restricted cubic splines were used to explore non-linear HbA1c-lipid relationships; mediation analysis estimated the TG/HDL-C contribution to the HbA1c-AIP pathway; and Net Reclassification Improvement (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.